Emerging evidence and clinical implications on how HMO modulate the immune system in infants with Cow's Milk Protein Allergy (CMPA)

Nestle Health Science Satellite Symposium June 9 at EAACI 2:30-3:30 PM CEST, save the date (Available to all HCP even those not registered to the EAACI congress).

The CINNAMON and PLATYPUS published studies (2022), highlight the evidence for the benefits of Human Milk Oligosaccharides (HMO) in infants with Cow’s Milk Protein Allergy (CMPA). HMO, through their enrichment of infant type bifidobacteria and associated metabolites enhance early immune development, strengthen immune defenses against infections and reduce antibiotic use.

Join us on Friday 9^th of June at EAACI, for the live stream of our Nestlé Health Science satellite symposium “How do HMO modulate the immune system in infants with Cow's Milk Protein Allergy (CMPA)? Emerging evidence and clinical implications”. Experts will share more about the latest evidence for the benefits of HMO in the management of Cow's Milk Protein Allergy (CMPA).